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Dixon et al., Antiviral Research 2019
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African Swine Fever Status (2016-2020)
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African Swine Fever in Africa
• Large DNA virus, Asfaviridae family
• Approximately 160 genes, number depending on 
isolate.
• 2 genotypes present in China, one in Europe.
• ASFV present in about 26 African countries.
• All 24 genotypes are present in Africa.
• There is a wildlife reservoir: warthogs and  bush pigs.
• Wild boars are susceptible. 
• Soft ticks of the genus Ornithodores are involved in 
transmission of ASFV.
From “Encyclopedia of Virology”
Chap.: African swine fever” by 



















































































Neighbor-Joining tree depicting the p72 gene relationships 
and geographical distribution of the major ASFV genotypes
p72 gene
Contribution: Livio Heath (ARC-OVI)
Genotype I
Genotype II,III, IV, V, 
VI, VII, XIX, XX, XIII 
Genotype IX, X
Genotype VIII, XI, XII, XIII, 
XV, XVI, XIV 






• High level of protection, 100 % in many 
cases in various doses
• Under optimal timing, 4 weeks post 
immunization
• Duration of immunity ?
• Safety
• Different dose studies for some vaccine 
candidates.
• Very different clinical readout system, some use 
clinical score systems with many parameters 
(King 2011 and Galindo-Cardiel 2013), others 
use single parameters, e.g., fever.
• Route of immunization
• Initially: intramuscularly 
• Orally route became interesting because of wild boar
• Less viremia using orally route
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ILRI ASFV Vaccine Activities
• Live vaccine  (CRISPR/Cas9 deletions) and synthetic approach
• Deletion of genes  for attenuation  
• Testing in established animal model
• Subunit vaccine – activities
• Screening of antigens
• Viral vectors as delivery
10
Isolated Virus
• Kenya 1033 (genotype IX) isolated by ILRI and 
DVS Kenya.
• Genotype IX and X are especially circulation in 
Eastern Africa.
• Isolated from a zone with outbreaks.
• Used as the challenging virus in the animal 
model
• Used as backbone for deletion of genes to 
generate attenuated viruses. 
Gallardo C et al. A.J. Biotech 2011 
Onzere C. et al. Virus Genes 2018
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ASFV Kenya 1033 – Virus Batch for Challenge 
• This virus is very similar to the other genotype IX and X viruses.
• Animal model was set up. Different doses were tested.
5 animal per group, intramuscular injection.






































































Scoring system: Galindo-Cardiel 2013
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Genomic Stability and Production Cell Lines 
Problems with instability of genomes in cell lines Progress on production cell lines
ZMAC – pig macrophage cell line
MA-104 cell line (Green monkey kidney epithelial 
cell line)
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Scoring system: King et al. 2011
Virus batch for challenge experiments
Virulence of WSL Adapted WT-Virus







































Challenge with wild type virus. 
Open circles: WSL cell line grown 
virus , Solid squares: Macrophage 
grown virus
• WSL (from FLI) is a fetal wild boar lung cell line, not immortalized.
• ASFV Kenya 1033 was adapted to WSL (20+ passages)
• 102 TCID50 was chosen to test if the virus grown in WSL cells was still lethal
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Virus batch for challenge experiments












Macrophage grown ASFV - 4 days WSL grown ASFV -  4 days
MOI 0.1 MOI 0.25 MOI 1 MOI 2.5 MOI 5
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Transfection with guide RNA 
and GFP donor DNA
Stable CAS transfected 
cell line (WSL)
Check for GFP insert 
with PCR over junction






Constructed 7-10 different viruses
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➢ Capacity to efficiently perform genome-wide changes in the virus genome in 
a combinatorial manner to understand virus biology. 
➢ Capacity to produce clinically-relevant viruses without extensive passaging 
in tissue culture. 
➢ Streamlines process to generate various designer vaccine candidates and 
oncolytic viruses. 
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First Viruses: Experimental Setup
Day    -21                    0                                           31                                   51 
Quarantine           Clinical scoring             Clinical scoring   
Immunisation (1 injection) Challenge
104 ASF1033_∆CD2v               (9x) 102 ASF1033 (8x)
104 ASF1033_∆CD2v∆A238L  (9x) 102 ASF1033 (8x)
PBS (9x) 102 ASF1033 (8x)
CD2v 
Immunomodulatory molecule promoting apoptosis of 
lymphocytes. 
A238L
Mimic NFκB subunit, inhibits NFκB activity, which is 
crucial in the pro-inflammatory response.
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Clinical Scores After Immunization
























































































Clinical Scores  After Challenge








































































































































































• ∆CD2v is more efficient than the double knockout but less attenuated. 
87.5% protection versus 50%.

























Second viruses: Experimental Setup
Day    -21                    0                                           31                                   51 
Quarantine           Clinical scoring             Clinical scoring   
Immunisation (1 injection) Challenge
103 ASF1033_∆X              (7x) 102 ASF1033 _∆X (6x)
103 ASF1033_∆Y              (7x) 102 ASF1033 _∆Y (6x)
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Richard Bishop, now WSU 
Edward Okoth 
THANK YOU
